<SEC-DOCUMENT>0001628280-25-018671.txt : 20250421
<SEC-HEADER>0001628280-25-018671.hdr.sgml : 20250421
<ACCEPTANCE-DATETIME>20250421172913
ACCESSION NUMBER:		0001628280-25-018671
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250421
FILED AS OF DATE:		20250421
DATE AS OF CHANGE:		20250421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		25854502

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk04x21x2025.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie93325eaa36047e1a29e8c0edc543e71_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of April, 2025.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 21, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a04-2025cybinosmindprfinal.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated April 21, 2025</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a04-2025cybinosmindprfinal.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i95de3ae9025f46638ca0716597982737_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:110px;margin-bottom:5pt;vertical-align:text-bottom;width:190px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%"> - Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need -</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; April 21, 2025 &#8211; </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NYSE American&#58;CYBN) (Cboe CA&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin. &#34;Osmind&#8217;s extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments. End-to-end mapping in key areas of clinic workflow and patients&#8217; journey such as pharmacy, fulfillment, patient access and reimbursement will lay the groundwork for commercialization of our lead clinical programs&#58; CYB003 in Phase 3 development for the adjunctive treatment of major depressive disorder, and CYB004 in a Phase 2 study for generalized anxiety disorder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> We look forward to a productive collaboration that leads to meaningful progress in transforming the treatment paradigm for patients with mental health disorders.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With 52.9 million people in the U.S., or nearly one in five Americans </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, living with a mental illness, there remains a significant unmet need in addressing the mental health crisis. Many patients do not experience relief with the standard of care, highlighting a need for innovation and improved therapeutic options.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;We are thrilled to partner with Cybin&#59; together, we are aligning incentives across stakeholders to help patients in need,&#8221; said Jimmy Qian, President of Osmind. &#8220;By preparing real-world care settings for next-generation neuropsychiatric interventions, Osmind is reducing friction and promoting practice success for clinicians, increasing access for patients, while supporting Cybin&#8217;s market penetration and commercial launch. Osmind and Cybin share a common mission to scale cutting-edge mental health treatments to as many patients as possible. We are delighted to support Cybin&#8217;s differentiated research, development, and commercialization efforts.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Opportunity to Address Unmet Needs in Mental Health</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:11.36pt">Globally, it is estimated that over 300 million people suffer from major depressive disorder (MDD)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. The global market size for major depressive disorder was estimated at $5.15 billion in 2024 and is projected to rise to $11.09 billion by 2033.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:11.36pt">An estimated 21 million Americans experienced at least one major depressive episode in 2021.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> About two-thirds of patients with MDD do not experience relief with initial antidepressant treatment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">5</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:11.36pt">It is estimated that 6.8 million people in the U.S. suffer from generalized anxiety disorder (&#8220;GAD&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Approximately 50% of patients with GAD are unresponsive to first line treatment with selective serotonin reuptake inhibitors (&#8220;SSRIs&#8221;) and serotonin-norepinephrine reuptake inhibitors (&#8220;SNRIs&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">7</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Osmind</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind&#8217;s psychiatry-tailored software and services, used by leading psychiatry practices across the U.S., help improve patient outcomes while driving practice success. Osmind's network of over 800 clinics comprises the country's largest network of interventional psychiatry practices. Simultaneously, Osmind's clinic network, point-of-care software, and real-world data support life sciences companies in developing and scaling access to cutting-edge treatments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Sources</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1.</font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt;text-decoration:underline">https&#58;&#47;&#47;www.nimh.nih.gov&#47;health&#47;statistics&#47;mental-illness</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">World Health Organization. (2017). Depression and other common mental disorders&#58; global health estimates. World Health Organization. </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">https&#58;&#47;&#47;iris.who.int&#47;handle&#47;10665&#47;254610</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Business Research Insights. (2025, March 24). Major depressive disorder market size, share, growth, and industry analysis by type (antidepressant drugs, SSRIs, SNRIs, benzodiazepines and others), by application (hospitals, clinics and others), regional insights and forecast from 2025 to 2033. Major Depressive Disorder Market Size to Hit USD 11.09 Bn by 2033. </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">https&#58;&#47;&#47;www.businessresearchinsights.com&#47;market-reports&#47;major-depressive-disorder-market-108486</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4.</font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt;text-decoration:underline">https&#58;&#47;&#47;www.nimh.nih.gov&#47;health&#47;statistics&#47;major-depression</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Little A. (2009). Treatment-resistant depression. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">American family physician</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, 80(2), 167&#8211;172.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">6.</font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt;text-decoration:underline">https&#58;&#47;&#47;adaa.org&#47;understanding-anxiety&#47;generalized-anxiety-disorder-gad</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:8.84pt">Ansara E. D. (2020). Management of treatment-resistant generalized anxiety disorder. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">The mental health clinician</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, 10(6), 326&#8211;334. https&#58;&#47;&#47;doi.org&#47;10.9740&#47;mhc.2020.11.326</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cautionary Notes and Forward-Looking Statements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company&#8217;s ability to successfully leverage Osmind&#8217;s clinical network, software and data to accelerate its clinical programs&#59; commercialization of its clinical stage programs&#59; and the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the spread of a pandemic on the Company's operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company&#8217;s annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> and with the U.S. Securities and Exchange Commission on EDGAR at </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed.&#160; If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;&#8239;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601&#160;</font></div><div style="text-align:justify"><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M$TF4"PGS:(SSH7 @6CIJHV&]U7B,^N(BM[%=^A7,WL#Q[TLX AJOE,.A\8;
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M<7CC.,PNO+ET7XRS&XYF9.)E2;M[-BX#C3%%#VQ\$?IZB'<7SM^R38[;-SX
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%1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
